The U.S. Trade Representative has taken the unusual move of stating that revised U.S.-Mexico-Canada Agreement (USMCA) rules on biologic drug patent protections do not change regulations for drug pricing in the U.S. That’s likely a response to House Democrats’ concerns and comes against the backdrop of other issues such as labor protection that may hold up USMCA’s passage through Congress. Aside from intellectual property rights the trade of pharmaceuticals in USMCA is minor in context. Imports from Canada and Mexico accounted for just 6.3% of the total $71.2 billion ...